{"id":"fluquadri","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness or erythema"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FluQuadri contains inactivated (killed) virus particles or viral antigens from four influenza strains (two A strains and two B strains). When administered, it triggers the adaptive immune response, leading to production of neutralizing antibodies and cellular immunity against these circulating influenza variants. This provides protection against infection by matching the vaccine composition to predicted seasonal flu strains.","oneSentence":"FluQuadri is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:56.818Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT03457194","phase":"","title":"Optimising Protection for Pregnant Women and Infants With Maternal Vaccination","status":"UNKNOWN","sponsor":"Women's and Children's Hospital, Australia","startDate":"2018-08-28","conditions":"Obesity","enrollment":73},{"nctId":"NCT02957890","phase":"PHASE4","title":"Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2016-11-18","conditions":"Influenza, Human","enrollment":400},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FluQuadri","genericName":"FluQuadri","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"FluQuadri is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}